BRISTOL MYERS SQUIBB
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study)
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 252
- Registration Number
- NCT00207142
- Locations
- 🇬🇧
Local Institution, London, Greater London, United Kingdom
MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2008-11-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 68
- Registration Number
- NCT00207103
- Locations
- 🇺🇸
Premiere Oncology, Santa Monica, California, United States
🇺🇸University Of Wisconsin Comprehensive Center, Madison, Wisconsin, United States
🇬🇧Local Institution, Manchester, Greater Manchester, United Kingdom
Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2013-03-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT00198289
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
Clinical Trial Comparing Safety and Pharmacokinetics of Standard Antibiotic Therapy, Plus Aurexis® or Placebo, for Treatment of Staphylococcus Aureus Bacteremia (SAB)
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2013-03-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 60
- Registration Number
- NCT00198302
An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 16
- Registration Number
- NCT00162201
- Locations
- 🇬🇧
Local Institution, Leeds, Essex, United Kingdom
ATV/Ritonavir Nevirapine Interaction (USPAC)
- Conditions
- Interventions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 46
- Registration Number
- NCT00162149
- Locations
- 🇬🇧
Local Institution, London, Greater London, United Kingdom
PPAR-COMBO With Sulfonylurea
- Conditions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2010-09-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 534
- Registration Number
- NCT00162175
- Locations
- 🇬🇧
Local Institution, Swan Lane, United Kingdom
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
- Conditions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2014-01-09
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00162227
- Locations
- 🇺🇸
Children'S Hospital, Boston, Massachusetts, United States
🇺🇸State University Of New York At Stony Brook, Stony Brook, New York, United States
🇺🇸Metro Health Medical Center, Cleveland, Ohio, United States
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada
- Conditions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2014-01-09
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00162188
- Locations
- 🇨🇦
Local Institution, Montreal, Quebec, Canada
Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment
- Conditions
- Interventions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2010-09-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 21
- Registration Number
- NCT00162097
- Locations
- 🇮🇹
Local Institution, Milano, Italy
🇺🇸Uthscsa, San Antonio, Texas, United States
🇺🇸Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States